OCCLUSION OF POLYMERIC CAPSULES IN CALCITE SINGLE CRYSTALS FOR STORAGE OF ACTIVE PHARMACEUTICAL INGREDIENTS
Main Article Content
Keywords
Active Pharmaceutical Ingredients (API), polyvinylidene Chloride (PVdCI), and Polyethene glycol (PEG), safely and securely store API
Abstract
Polymeric capsule occlusion in calcite single crystal is a novel technique for the storage of “Active Pharmaceutical Ingredients (API)”. This technique uses the physical properties of calcite crystals to safely and securely store API for a longer period of time. The calcite crystals are able to form a tight seal around the polymeric capsule, preventing moisture and other environmental contamination from entering the capsule and degrading the API. The calcite crystals also display a high degree of optical clarity, allowing for easy visual identification of the API, and providing an efficient way to monitor the API’s condition. The polymeric capsules used in this technique are typically made from either “polyvinylidene Chloride (PVdCI)” or “Polyethene glycol (PEG)”. These materials are chosen for their chemical inertness, meaning they will not react with the API. This ensures that the API remains stable and potent cover time. The capsules are also designed to be both flexible and rigid, providing the necessary protection while still allowing the API to be released when needed. The occlusion process itself is relatively easy and straightforward. The polymeric capsule is carefully inserted into the calcite crystal, and the crystal is then heat treated to form a tight seal. This creates a secure environment in which the API can be stored for extended periods of time. Polymeric capsule occlusion in calcite single crystals is an effective and efficient way to store APIs safely and securely. This technique provides an ideal environment for the API to remain stable and potent for a longer period of time.
Downloads
References
1. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-lerm improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86. 2. Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-et blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:661-8. 3. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, slL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-15. 4. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between infiammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008; 10:R104. 5. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis .Ann Rheum Dis 2004;63:1438-44. 6. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylicis Functional Index. J Rheumatol 1994;21(12):2281-2285. 7. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is c combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999;38:878-82. 8. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;(2):CD004800. 9. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007;66:1393-7. 10. de Vries MK, van Eijk IC, van der Horst-Eruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009;61:1484-90. 11. Dougados M, Boumer P. Amor B. Sulphosalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. BMJ 1986;293:911-14. 12. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27. 13. Gossec L, van der Heijde D. Melian A, Krupa DA, James MK, Cavanaugh Jr PF, et al. The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005;62:1563-7. 14. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewe R, Dougados M, Mielants H, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum2004;51:154-9. 15. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylities (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694-8. 16. Jones SD, Calin A, Steiner A. An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDÁI, BASFI): excellent Cronbach's alpha scores. J Rheumatol 1996;23:407. 17. Maksymowych WP, Landewé R. Conner-Spady B, et al. Serum Matrix metalloproteinase 3 is an independent predictor of structural darnage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:1846-53. 18. Nissila M. Lehtinen K Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. MSulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-16. 19. Park MC, Lee SW, Choi ST, et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 2007;36:101-6. 20. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Sieper J. Magnetic resonance imaging (MRI) in predicting a major clinical responce to anti-TNF-treatment in ankylosing spondylitis.Ann Rheum Dis 2007.E-pub ahead of print. 21. Rudwaleit M. Schwarzlose S, Hilgert ES, Listing J, Braun ), Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:126-81. 22. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4. 23. Van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions.Ann Rheum Dis 2008;67:489-93. 24. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylities after treatment with infliximab. Ann Rheum Dis 2008; 67:511-517. 25. Yang C, Gu J. Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004:51:691-9.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.